Published in J Cancer on December 09, 2016
Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (2004) 125.23
The structure of haplotype blocks in the human genome. Science (2002) 50.88
Cancer-related inflammation. Nature (2008) 34.21
COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res (2014) 10.77
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91
Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol (2002) 6.09
Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered (2008) 5.89
BRAF mutation in thyroid cancer. Endocr Relat Cancer (2005) 5.65
Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg (2014) 5.18
A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res (2008) 5.05
Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer (2013) 4.46
Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol (2003) 2.67
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res (2007) 2.61
Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol (2008) 2.58
The KRAS oncogene: past, present, and future. Biochim Biophys Acta (2005) 2.05
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene (2005) 1.99
Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol (2007) 1.92
Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab (2003) 1.91
Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg (2008) 1.85
Nonradiation risk factors for thyroid cancer in the US Radiologic Technologists Study. Am J Epidemiol (2009) 1.74
Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol (2010) 1.70
Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res (2009) 1.65
Thyroid cancer and inflammation. Mol Cell Endocrinol (2009) 1.37
Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol (2009) 1.37
The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene (2000) 1.23
Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am (2008) 1.19
BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma. Endocr Pathol (2013) 1.13
BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res (2008) 1.12
A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer. Tumour Biol (2013) 0.98
Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle (2014) 0.98
A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. Tumour Biol (2013) 0.92
Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. Endocr Pathol (2010) 0.91
Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis. Clin Chem Lab Med (2013) 0.89
Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid (2014) 0.89
Association of the ATM gene polymorphisms with papillary thyroid cancer. Endocrine (2013) 0.87
Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer. Med Oncol (2014) 0.86
Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population. Anticancer Res (2013) 0.85
Thyroid cancer review 1: presentation and investigation of thyroid cancer. Int J Clin Pract (2005) 0.85
Are the SNPs of NKX2-1 associated with papillary thyroid carcinoma in the Han population of Northern China? Front Med (2014) 0.84
Absence of germline mutations in genes within the MAP kinase pathway in familial non-medullary thyroid cancer. Cell Cycle (2006) 0.81
Lack of mutational events of RAS genes in sporadic thyroid cancer but high risk associated with HRAS T81C single nucleotide polymorphism (case-control study). Tumour Biol (2012) 0.79
Association of rs712 polymorphism in Kras gene 3'-luntranslated region and cancer risk: a meta-analysis. J BUON (2015) 0.78
Association study of chemokine (C-C motif) ligand 5 gene polymorphism and papillary thyroid cancer. J Invest Surg (2013) 0.78
Thyroid cancer: a molecular perspective. Mol Cell Endocrinol (2010) 0.78
[Comparative study of somatic oncogene mutations in normal thyroid tissues and thyroid neoplasms]. Orv Hetil (2011) 0.76
Copy number alteration and uniparental disomy analysis categorizes Japanese papillary thyroid carcinomas into distinct groups. PLoS One (2012) 0.76